Free Trial

PureTech Health (LON:PRTC) Shares Cross Above Fifty Day Moving Average - What's Next?

PureTech Health logo with Medical background

Key Points

  • PureTech Health shares rose above their fifty-day moving average of GBX 135.12 during trading, reaching a high of GBX 146.40 before closing at GBX 138.
  • The company's insider activity included the purchase of 167,739 shares by Bharatt Chowrira at a significantly lower price of £1 ($0.01) per share, which indicates strong insider confidence.
  • PureTech Health has a strong liquidity position with a current ratio of 3.68 and a market capitalization of £414.53 million, although it is currently trading at a negative price-to-earnings ratio of -5.66.
  • Five stocks we like better than PureTech Health.

PureTech Health plc (LON:PRTC - Get Free Report)'s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 135.12 ($1.80) and traded as high as GBX 146.40 ($1.95). PureTech Health shares last traded at GBX 138 ($1.83), with a volume of 233,641 shares changing hands.

PureTech Health Trading Down 0.7%

The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The business has a fifty day simple moving average of GBX 135.16 and a 200 day simple moving average of GBX 134.21. The company has a market cap of £411.52 million, a P/E ratio of -5.62 and a beta of 1.02.

Insider Buying and Selling

In other news, insider Bharatt Chowrira purchased 167,739 shares of the stock in a transaction dated Thursday, July 3rd. The shares were bought at an average cost of GBX 1 ($0.01) per share, for a total transaction of £1,677.39 ($2,229.39). 15.93% of the stock is currently owned by corporate insiders.

About PureTech Health

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

See Also

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines